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Summary
Bovine tuberculosis (bTB) is highly prevalent in intensive dairy farms of the urban
“milk-sheds” in Ethiopia, and vaccination could be a cost-effective disease control
strategy. In the present study, the efficacy of Bacillus Calmette–Guerin (BCG) to pro-
tect against bTB was assessed in Holstein–Friesian calves in a natural transmission set-
ting. Twenty-three 2-week-old calves were subcutaneously vaccinated with BCG
Danish SSI strain 1331, and matched 26 calves were injected with placebo. Six weeks
later, calves were introduced into a herd of M. bovis-infected animals (reactors) and
kept in contact with them for 1 year. In vitro and in vivo immunological tests were
performed to assess immune responses post-vaccination and during exposure. Suc-
cessful vaccine uptake was confirmed by tuberculin skin test and IFN-c responses in
vaccinated calves. The kinetics of IFN-c responses to early secretory antigen target 6
and culture filtrate protein 10 (ESAT6 and CFP10, respectively) and tuberculin skin
test responses post-exposure suggested that the animals were infected early after
being placed in contact with the infected herd as immunological signs of infection
were measurable between 2 and 4 months post-initial exposure. Protection was
determined by comparing gross and microscopic pathology and bacteriological burden
between vaccinated and control calves. BCG vaccination reduced the proportions of
tissues with visible pathology in vaccinates compared to control calves by 49%
(p < .001) with 56%, 43%, 72%, and 38% reductions in the proportion of lesioned
tisues in head, thoracic, abdominal lymph nodes, and lungs, respectively (p-values
.029–.0001). In addition, the lesions were less severe grossly and microscopically in vac-
cinated calves than in non-vaccinated calves (p < .05). The reduction in the overall inci-
dence rates of bTB was 23%, 28%, and 33% on the basis of the absence of gross
pathology, M. bovis culture positivity, and histopathology, respectively, in vaccinated
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animals. In conclusion, BCG vaccination reduced the frequency and severity of the
pathology of bTB significantly, which is likely to reduce onwards transmission of the dis-
ease.
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1 | INTRODUCTION
Ethiopia, with over 90 million people, is a typical example of the
demographics in most developing countries in Africa and Asia with
the human population increasing by 3.2% per year (CSA, 2011), lead-
ing to increased demand for food production. Hence, cereal crop
production has been prioritized at the cost of grazing land for live-
stock (Tschopp et al., 2010), leading to overstocking and overgrazing
of that land, thereby compromising the development in the Ethiopian
livestock sub-sector. For this reason, intensification of livestock pro-
duction is considered to be the best option. Thus, the number of
intensive dairy farms in and around urban centres is increasing.
These emerging dairy farms hold cattle breeds optimized for
increased milk production, as the milk production potential of
indigenous zebu breeds is by far lower than that of either Holstein–
Friesian or crosses between these exotic breeds and indigenous zebu
breeds. Moreover, as the extensive cattle husbandry management of
the Ethiopian farmers cannot satisfy the milk demand of the growing
population, the government is encouraging the establishment of
intensive dairy farms by the private sectors. However, both the
increase in the number of exotic breeds and the intensification of
dairy farming are associated with increased prevalence of cattle
diseases such as bovine tuberculosis (bTB) (Ameni et al., 2007;
Cosivi et al., 1998; Firdessa et al., 2012).
BTB is predominantly caused by M. bovis and is characterized by
the development of granulomatous lesions in the respiratory tract
and also in other tissues of the animal. Globally, this disease impacts
in three major ways, namely as zoonotic TB in humans; direct eco-
nomic losses due to reduced livestock productivity; and indirect eco-
nomic losses due to livestock trade restrictions.
The increased number of more susceptible exotic breeds
together with the increased intensification of production demands
prioritization of improved bTB control strategies focusing primarily
on intensive dairy farms. In developed countries, the control of bTB
is based on a test-and-slaughter strategy, which would be too costly
to be applied on a national level in Ethiopia or in any other develop-
ing country. Hence, there is a need for exploring alternative control
strategies such as routine testing and surveillance, pre-movement
testing, movement restriction of infected herds, and vaccination, all
of which could be combined with better bio-security and farm
hygiene. In the present study, we have evaluated the performance
of BCG in protecting cattle against bTB in a natural transmission set-
ting by exposing vaccinated and non-vaccinated calves to a cattle
herd known to be bTB infected, which complements our previous
study (Ameni, Vordermeier, Aseffa, Young, & Hewinson, 2010).
2 | MATERIALS AND METHODS
2.1 | Study setting and sources of experimental calves
The experiment was conducted at Sebeta Agro Industry PLC, a private
farm located in Sebeta about 20 km south-west of Addis Ababa, Ethio-
pia. At the start of this challenge experiment, its dairy herd consisted
of 72 Holstein–Friesian cattle or crosses; thereof, with the zebu breed,
all animals were positive in the single intradermal comparative tuber-
culin test (SICTT), as described further below. However, during the
course of experiment the number of reactor animals decreased gradu-
ally, and to maintain a reactor to sentinel ratio > 1, 15 skin test reactor
animals from Holeta Agricultural Research Centre were introduced
~6 months into the challenge experiment.
Dairy farms located around Addis Ababa were randomly selected
and tested for bTB using the SICTT. Thereafter, the experimental
calves were recruited from seven bTB negative farms located around
Addis Ababa. A total of 49 Holstein–Friesian calves were recruited
for the experiment. The calves were allocated to experimental and
control groups randomly using a lottery system. The allocation was
carried out in batches of 10 calves, as all calves could not be
recruited at once. Twenty-three calves were allocated into a vacci-
nated group while the remaining 26 calves were used as controls. All
the calves were tested negative for bTB when tested with the
Bovigam IFN-c test prior to their recruitment into the experiment.
The experiment was approved both by Ethics Committee of the
Armauer Hansen Research Institute and by the Ethical Review Board
at the Animal and Plant Health Agency.
2.2 | Vaccination schedule of the neonates
All calves of the vaccinated group were vaccinated within 2 weeks of
birth by subcutaneous injection with 1–4 9 106 CFU BCG Danish SSI
1331(Staten’s Serum Institute [SSI], Copenhagen, Denmark), which
was supplied as freeze-dried preparation and reconstituted in Sauton’s
medium as per the manufacturer’s instruction. Until calves were intro-
duced into the reactor herd, at 2 months of age, they were kept iso-
lated in a communal calf pen. During this time, the calves were fed
with milk, from PPD-negative cows, concentrate, and grass on the
basis of their age. At around 6 weeks post-vaccination (when they
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were about 2 months old), the calves were moved to the bTB-positive
herd and kept in contact with reactor animals for about 1 year.
2.3 | SICTT in calves
Experienced veterinarian who was blinded with regard to the vacci-
nation status of each calf performed the SICTT. The test was per-
formed four times: at sixth week post-vaccination and prior to
exposure to infected cows, and after 4, 8, and 12 months of expo-
sure to reactors. On each occasion, 0.1 ml avian purified protein
derivative (APPD, 25,000 IU/ml, Thermo Fisher, Lelystad, The
Netherlands) was injected into the skin intradermally in the cranial
part of the neck while 0.1 ml bovine purified protein derivative
(BPPD, 20,000 IU/ml, Thermo Fisher) was injected intradermally in
the caudal part of the neck, and the increases in skin thickness were
measured 72 hr post-PPD administrations. Results were interpreted
according to the recommendations of the World Organization for
Animal Health (OIE, 2009).
2.4 | Whole-blood culture and IFN-c test
IFN-c test was performed on animals on a regular basis to monitor
the outcome of vaccination as well as the outcome of the exposure
to the reactors. Blood samples were collected from the jugular vein
into heparinized vacutainers and then transported to the laboratory
for stimulation within 8 hr of collection. For stimulation, 250ll of whole
blood was dispensed in duplicate into 96-well flat-bottom culture
plates. Then, 25-ll aliquots of mycobacterial antigens were added into
each well to give the final assay concentrations of 10lg/ml of APPD,
10lg/ml of BPPD, and 10lg/ml of ESAT6/CFP10 peptide cocktail (5lg
each peptide/ml). Lectin from Phytolacca americana (pokeweed; Sigma)
at 5lg/ml and saline (both 25ll) were used as positive and negative
controls, respectively. Cultures were incubated at 37°C in a humid 5%
CO2 atmosphere for 48 hr, and supernatants were harvested and fro-
zen. IFN-c in the supernatants were measured by an enzyme-linked
immunosorbent assay using Bovigam test kit (Prionics, Schlieren,
Switzerland) in accordancewith the manufacturer’s instructions.
2.5 | Post-mortem examination and pathology
scoring
At the end of one-year exposure period, the calves were transported
to the post-mortem room at the National Animal Health Diagnostic
and Investigation Centre (NAHDIC), which is located close to the
experiment site. The calves were euthanized humanely and examined
for gross lesion of bTB by a veterinary pathologist and two addi-
tional veterinarians with expertise on bTB. All three experts were
blinded to the vaccination status of the calves. Up to four calves
were slaughtered per day and subjected to detailed post-mortem
examination. The lungs and lymph nodes (LNs) were removed for
investigation of TB lesions. All seven lobes of the lungs were
inspected at the surface and palpated for the presence of TB lesions
within the internal parenchyma. Each lobe was then sectioned into
1–2-cm thick slices to facilitate the detection of TB visible lesions
(VL). Similarly, LNs, including the left and right parotid, left and right
mandibular, left and right lateral retropharyngeal, left and right med-
ial retropharyngeal, cranial and caudal mediastinal, left and right
bronchial, hepatic, and mesenteric LNs, as well as left and right ton-
sils, were sliced into thin sections and inspected for the presence of
VLs. When gross lesions suggestive of bTB were found in any of the
tissues, the animal was classified as “VL.” Any animal in which TB-
like lesion(s) were not found was classified as “NVL” (none visible
lesions). The severity of gross lesions was scored by a semi-quantita-
tive scoring procedure as previously described by Vordermeier et al.
(2002). Briefly, lesions in the lobes of the lungs were scored separately
as follows: 0, no visible lesions; 1, no gross lesions but lesions apparent
on slicing of the lobe; 2, fewer than five gross lesions; 3, more than five
gross lesions; and 4, gross coalescing lesions. The scores of the individ-
ual lobes were added up to calculate the lung score. Similarly, the
severity of gross lesions in individual LN was scored as follows: 0, no
gross lesion; 1, a small lesion at one focus (just starting); 2, small
lesions at more than one focus; and 3, extensive necrosis. Individual
LN scores were added up to calculate the total LN score for each LN/
tissue category. Finally, LN and lung pathology scores were added
together to give the total pathology score per animal.
2.6 | Histopathological examination and grading of
granuloma
For histopathology examination, tissue samples from organs display-
ing TB-like gross lesions were collected and immersed in fixative
(10% neutral buffered formalin) for 7 days before being processed
and embedded in paraffin wax. Four-micron sections were cut and
routinely stained with haematoxylin and eosin (H&E) and Ziehl–Neel-
sen (ZN) for the detection of TB granuloma and acid-fast bacilli
(AFB), respectively. Slides were examined by light microscopy to
determine the distribution of granuloma development stages as
defined by Wangoo et al. (2005). Thus, these four stages of granulo-
mas were quantified and analysed as previously described (Aranday-
Cortes et al., 2013). Briefly, Stage I (initial) granulomas comprised
clusters of epithelioid macrophages (MΦs), few neutrophils, and
occasional Langhans’ multinucleated giant cells (MNGCs). Stage II
(solid) granulomas were more regular in shape and surrounded by a
thin and incomplete capsule. The cellular composition was primarily
epithelioid MΦs, Langhans’ MNGCs giant cells present, and some
infiltration of lymphocytes and neutrophils. Necrosis was minimal or
not present. Stage III (necrotic) granulomas were all fully encapsu-
lated with central areas of necrosis. The necrotic centres were sur-
rounded by epithelioid MΦs and Langhans’ MNGCs, and a peripheral
zone of MΦs, clustered lymphocytes, and isolated neutrophils
extended to the fibrotic capsule. Stage IV (mineralized) granulomas
were completely surrounded by a thick fibrous capsule and displayed
central areas of caseous necrosis with extensive mineralization. The
central necrosis was surrounded by epithelioid MΦs and Langhans’
MNGCs cells with a peripheral zone of MΦs and dense clusters of lym-
phocytes just inside the fibrous capsule. They were frequently
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multicentric, with several granulomas coalescing. The total number
and developmental stage of granulomata within each slide were
counted.
2.7 | Isolation of mycobacteria
Isolation of mycobacteria from the LNs and lung tissues was per-
formed in accordance with OIE protocols (2009). Briefly, tissue spec-
imens were collected into sterile universal bottles in 5 ml of a 0.9%
saline solution and then transported to the laboratory for bacterial
isolation. Individual LN and lung samples were cultured. In VL cases,
two or three tissues with lesion were processed for culturing per
individual calf. In NVL cases, sections of eight LNs (left and right lat-
eral retropharyngeal, left and right medial retropharyngeal, cranial
and caudal mediastinal, and left and right bronchial) were cultured
per individual calf. The LNs were sectioned into pieces with sterile
blades and then homogenized with a pestle and a mortar. The homo-
genate was decontaminated by adding an equal volume of 4% NaOH
and centrifuged at 1,106 g for 15 min. The supernatant was dis-
carded, while the sediment was neutralized with 1% (0.1 N) HCl with
phenol red as an indicator. Neutralization was achieved when the col-
our of the solution changed from purple to yellow. Thereafter, 0.1 ml
of suspension from each sample was spread onto duplicate slants of
Lowenstein–Jensen medium (OIE, 2009); one was enriched with
sodium pyruvate, while the other was enriched with glycerol. Cul-
tures were incubated aerobically at 37°C for up to 8 weeks with
weekly observation for growth of mycobacterial colonies. Any culture
positive sample was stained by ZN staining, and the presence of iso-
lates was confirmed by the demonstration of acid-fast bacilli (AFB) in
the smears of colonies. Heat-killed AFB positive samples were inves-
tigated by multiplex PCR for the presence or absence of RD4 (Fird-
essa et al., 2012), a chromosomal deletion that defines M. bovis.
2.8 | Statistical analysis
To estimate the incidence of bTB per group, the number of calves
that developed TB was divided by the total number of calves in the
group. The efficacy of the vaccine was estimated using the formula
described by Orenstein et al. (1985), which considers the incidence
rates of the disease in question in the vaccinated and in unvaccinated
calves; i.e., the efficacy of a vaccine is the percentage reduction in
the incidence rate of a disease among vaccinated calves as compared
to the incidence rate in unvaccinated calves. The formula used for
calculating vaccine efficacy (VE) in this study was VE = (ARU-ARV/
ARU) 9100%, where ARU is attack (incidence) rate in the unvacci-
nated group and ARV is the attack (incidence) rate in the vaccinated
group. Chi-squared (v2) test was used to compare the percentages of
gross pathology in different tissues of vaccinated and control calves.
In addition, the incidence rates of bTB and efficacies of BCG in vacci-
nated and control calves were compared using v2 test. Comparisons
of severity of gross lesion between tissues of vaccinated and control
calves were made using non-parametric t test with Mann–Whitney
comparison post-test. Means of optical density at 450 nm (OD450)
values for the IFN-cresponses in the vaccinated and control groups
were compared using unpaired t test with Welch’s correction. In
addition, the means of change in skin thickness following skin test in
vaccinated and control calves were compared using unpaired t test
with Welch’s correction. A v2 test for trend statistical analysis was
performed to compare the distribution of Stage I–IV lesions in vacci-
nated and control groups, using Prism 6.0 (GraphPad, San Diego, CA,
USA). Statistical significance was fixed at p < .05.
3 | RESULTS
3.1 | Immune responses post-vaccination
The SICTT and IFN-c responses to APPD and BPPD were investi-
gated in BCG-vaccinated and control calves following vaccination. In
the vaccinated group, IFN-c responses to BPPD started to rise
1 week after BCG vaccination, peaked at the third and fourth week
post-vaccination (data not presented). In addition, all calves were
SICTT tested 6 weeks post-BCG vaccination. As expected, the SICTT
responses in the vaccinated calves were statistically significantly
increased compared to the control animals (Figure 1a/b, p = 0.003;
unpaired t test) that all tested SICTT negative. Taken together, the
IFN-c release assay and SICTT result post-vaccination demonstrated















































F IGURE 1 Means of change in skin thickness (mm) following the single intradermal comparative tuberculin test (SICTT) in vaccinated and
control calves at sixth week post-vaccination with BCG. Skin thickness as shown individually (a) and in group (b) was significantly higher in
vaccinated calves than in control calves (p = .0025)
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F IGURE 2 Single intradermal comparative tuberculin testing (SICTT) responses in vaccinated and control calves with visible (VL) and non-
visible lesions (NVL) The calves were tested with SICTT at the fourth (a), eighth (b) and 12th (c) month post-exposure to infected herd. The
means of change in skin thickness following SICTT were significantly greater (unpaired t test with Welch’s correction) in control calves with VL
than in control calves with NVL at eighth (p = .002) and 12th (p = .002) month post-exposure to infected herd. However, although the mean
of change in skin thickness after SICTT was greater in vaccinated calves with VL than in vaccinated calves with NVL at all the months tested,





























































































































































































F IGURE 3 Kinetics of IFN-c response to ESAT6/CFP10 peptide cocktail in vaccinated and control calves with visible lesions (VL) and non-
visible lesions (NVL) groups at various time points post-exposure to infected herds for one year. The means of IFN-c response estimated by
optical density (OD) measured at 450 nm were monitored for 12 months after the calves were exposed to the infected herd. The means of
the IFN-c responses are compared (unpaired t test with Welch’s correction) in control calves with VL and in control calves with NVL at the
second (a; p = .011), fourth (b; p = .15), sixth (c; p = .0002), eighth (d; p = .001), 10th (e; p = .0001) and 12th (f; p = .001) month post-exposure
to the infected herd. However, although vaccinated calves with VL demonstrated relatively stronger IFN-c responses than vaccinated calves
with NVL at the different months of exposure, the difference between these two groups was not significant at any of the months
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3.2 | Immune responses after vaccinated and
control calves were exposed to infected herd
The kinetics of skin test (SICTT) and IFN-c responses were deter-
mined during the 12 months in-contact period of BCG-vaccinated
and control calves with the M. bovis-infected herd. The results were
stratified according to the presentation of visible gross pathology at
the slaughter of the calves, i.e., the presence or absence of visible
lesions (VL or NVL, respectively). SICTT responses were determined
at month 4, 8, and 12 of the in-contact period. The results are
shown in Figure 2. SICTT responses increased in VL control animals
after 4 months exposure compared to NVL animals, although this
difference was not yet statistically significant (Figure 2a). However,
these responses were significantly higher at months 8 and 12 in VL
controls compared to their NVL counterparts (Figure 2b/c, p = .002
and .002, respectively). Indeed, no SICTT responses were induced in
the four NVL animals at months 8 and 12 (Figure 2b/c). SICTT
responses in VL BCG-vaccinated calves were elevated at months 4,
8, and 12 of the exposure period compared to their NVL group
mates. Differences between VL BCG and VL control animals were
not statistically significant.
The IFN-c responses towards stimulation with the RD1 antigens
ESAT-6 and CFP-10 were determined in vaccinated and control
calves 2, 4, 6, 8, 10, and 12 months after they were placed in con-
tact with the infected herd (Figure 3). These antigens are not recog-
nized after BCG vaccination, and their responses can be used to
monitor M. bovis infection. IFN-c responses in VL control calves
were signficantly elevated compared to NVL controls at all time
points (Figure 3a, c–f) except when measured 4 months after expo-
sure (Figure 3b). Similarly, increased IFN-c responses in VL compared
to NVL animals were observed in the BCG-vaccinated animals when
this parameter was determined at 4 to 12 months of the exposure
period (Figure 3b–f), although due to one outlying response, these
differences were not or not quite statistically significant (p values of
0.07 to 0.26, Figure 3). The data also suggested that IFN-c
responses of VL BCG animals were lower at all time points tested
compared to VL control animals (Figure 3b–f) and developed later
than in unvaccinated calves (Figure 3a), although these differences
were not statistically signficant.
Taken together with the corresponding SICTT data, the IFN-c
responses displayed by VL control animals were suggestive that
immune responses demonstrating M. bovis infection were detectable
from 2 (IFN-cresponses) to 4 months (SICTT) of exposure to the
infected herds.
3.3 | Efficacy of BCG in protecting against bovine
tuberculosis: full protection
To determine whether BCG vaccination imparted full protection
against bTB disease, we first determined the presence or absence of
visible, grosspathology (VL or NVL, respectively), microscopic pathol-
ogy, or the presence of M. bovis in tissues (Table 1). In the unvacci-
nated group, 85% (22/26) of calves presented as VL had microscopic
lesions typical of bTB and contained M. bovis in post-mortem tissues
(Table 1). By contrast, 65% (15/23), 57% (13/23), and 61% (14/23)
of the vaccinated calves presented gross pathology, microscopic
pathogy, or were M. bovis culture positive, respectively (Table 1).
These figures equate to 23%, 33%, or 28% protection, respectively,
when these three parameters are taken into account. While only the
difference in the frequency of microscopically lesioned calves is sta-
tistically signficant (p = 0.031), the data demonstrated a consistent
degree of protection against bTB disease following BCG vaccination.
3.4 | Distribution, frequency, and severity of typical
bTB lesions in vaccinated and control calves
Further assessment of BCG protection against bTB was carried out
by determining the reduction in the severity and within animal dis-
semination of disease. The severity of pathology was scored accord-
ing to Vordermeier et al. (2002) in post-mortem tissues of BCG-
vaccinated and non-vaccinated calves and was compared as pre-
sented in Figure 4. The pathology was more severe (p = 0.04;
Mann–Whitney test) in the thoracic lymph nodes of control calves
(median  SD, 1.5  3.72) than in the thoracic lymph nodes of vac-
cinated calves (0.0  1.13). While we observed similar reductions in
the severity of gross pathology in vaccinated calves also in head
lymph nodes and the lungs compared to unvaccinated controls,
these reductions did not reach statistical significance (Figure 4).
However, the total pathology scores that integrate the pathology
scores of the different tisses were significantly lower in vaccinated
as compared to control calves (Figure 4, p = 0.03; control calves
scores = 5.0  13.12; vaccinated calves = 3.0  2.15).
The protective effect of BCG vaccination on reducing gross
pathology was also confirmed when the frequencies of visible lesions
found in the examined tissues were compared between control and
BCG-vaccinated calves (Table 2). The percentages of lesioned tissues
found in the head, thoracic, and abdominal LNs, as well as in the
lungs, were signficantly reduced by 56%, 43%, 72%, and 38%,
respectively, when vaccinated calves were compared with the
TABLE 1 Efficacy of BCG in protecting against bTB
Vaccinated group (23) Control group (26)
Attack rate in vaccinated calves Attack rate in control in calves EfficacyPositive Negative Positive Negative
Gross pathology 15 8 22 4 65% 85% 23%
Culture 14 9 22 4 61% 85% 28%
Histopathology 13 10 22 4 57% 85% 33%
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control calves (Table 2; p < .03 to <.0001). Overall, this represents a
reduction in lesioned tissues by 49% (Table 2, p < .001). The data
presented in this section, therefore, confirm a clear and strong
protective effect of BCG on reducing the severity of the conse-
quences of M. bovis infection.
3.5 | Assessment of microscopic bTB lesions in
vaccinated and control calves
Tissues presenting with TB-like lesion upon gross pathological exam-
ination were further subjected to microscopic histopathological anal-
ysis. The distribution, frequency, and severity of microscopic lesions
were assessed, and the results are depicted in Figure 5. Microscopic
lesions were scored from Stage I to Stage IV according to the classi-
fication system by Wangoo et al. (2005).
More than 500 individual granulomata were scored. The majority
of granulomata were observed in the thoracic LNs (cranial mediasti-
nal, caudal mediastinal, cranial tracheobronchial, and left and right
bronchial) and the “head and neck” LNs (left and right parotid, and
mandibular and medial and lateral retropharyngeal). As only a very
low number of granulomata were observed in other tissues such as
the lung, liver, hepatic or mesenteric LNs, statistical analyses were
only performed using the data generated by scoring granulomata in
the head and neck LNs (Figure 5a) and thoracic LN (Figure 5b).
When the head and neck LNs were assessed, the distribution of
granulomata of different development stages was statistically signifi-
cantly different (p < .05) between vaccinated and control calves,
with a distinct enrichment of early stage (I and II) granulomata in the
vaccinated animals compared to controls in whom granulomata of
the most developed granuloma stage (IV) dominated (Figure 5a). By
contrast, no statistically significant difference between vaccinates
F IGURE 4 Severity of gross pathology of bTB in different tissues
of vaccinated and control calves. Mann–Whitney test was used to
compare the severity of pathology between vaccinated and control
calves in different tissues. The pathology was more severe (p = .04);
in the thoracic lymh nodes of control calves than in the thoracic
lymph nodes of vaccinated calves; total pathology was more severe
(p = .03) in tissues of control calves than in tissues of vaccinated
calves








of pathology Chi-square test p-value
Head lymph nodes (LN) 12.5% (23/184) 28% (59/208) 56% 14.86 .0001
Thoracic LNs 32% (37/115) 56% (73/130) 43% 14.18 .0002
Abdominal LNs 11% (5/46) 38% (20/52) 72% 9.78 .0017
Lung lobes 16% (26/161) 26% (47/182) 38% 4.77 .029
Total Pathology 18% (91/506) 35% (202/572) 49% 40.74 .0001
F IGURE 5 Frequency of occurrence of the different stages (I–IV) granulomas within the head, neck (a), and thoracic lymph nodes (b) of
vaccinated and control calves. The bars represent the percentage of granulomas within each developmental stage. A significant difference was
observed in the frequencies of lesions in the head and neck lymph nodes of the vaccinated and control groups (panel a, p < 0.05), but not in
the frequencies of the thoracic lymph nodes (b) between the vaccinated and control groups
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and controls was observed in the distribution of granuloma develop-
mental stages in the thoracic LNs (Figure 5b).
4 | DISCUSSION
In the present study, the efficacy of the BCG vaccine was evaluated
in Holstein–Friesian calves in a natural transmission setting. When
cellular immune responses were determined in vaccinated calves
before they were introduced into the infected herds, neither IFN-c
nor tuberculin skin test responses correlated with protection deter-
mined by post-mortem at the end of the in-contact period (VL ver-
sus NVL calves, data not shown). This therefore confirms that these
two parameters are poor predictors of protection.
Based on the development of ESAT-6-/CFP-10-specific IFN-c
responses following the exposure of calves to the infected herd, it
can be hypothesized that the infection events took place during the
first 2–4 months of calves being in contact with infected animals.
Interestingly, ESAT-6-/CFP-10-induced IFN-c responses developed
at a slower pace in vaccinated VL animals compared to VL control
calves. This could be because BCG vaccination reduced the extent
of pathology or led to a slower disease progression compared to
na€ıve calves. Either hypothesis is supported by earlier data, demon-
strating that the extent of in vitro IFN-c production after stimulation
with ESAT-6 directly correlated with the extent of pathology
(Vordermeier et al., 2002).
The efficacy of BCG in protecting against M. bovis infection
under a natural transmission setting was estimated using either gross
pathology, microscopic lesion of bTB, or isolation of M. bovis as
interpretation criteria. In the present study, the efficacy of BCG for
protection against disease was low, whereas its effect on reducing
the extent of pathology was significant. The average efficacy of BCG
to protect fully against bTB recorded in this study was around 30%.
This rate is considerably lower than the efficacy reported earlier by
similar studies conducted in Ethiopia (Ameni et al., 2010) and in Mex-
ico (Lopez-Valencia et al., 2010). This difference in full protection
between the present and the previous Ethiopian natural transmission
study (Ameni et al., 2010) could be attributed to differences in the
severity of bTB in the infected reactor herds that served as sources
of infection: Although similar ratios of calves to reactor cows were
maintained in both experiments, the severity of disease was heavier
in the herd used for the present study compared to the herd used for
the previous study. For example, overt clinical signs of bTB were
more prevalent in the infected herd used in the present study. Never-
theless, both the present and the earlier studies (Ameni et al., 2010)
results are within the efficacy range of BCG (0% and 75%) reported
from experimental studies and trials in cattle conducted by different
researchers in different countries between 1959 and 2002 (reviewed
by Hewinson, Vordermeier, & Buddle, 2003). Thus, the result of the
present study may be reflective also of the inherent variability of
BCG to impart protection at population and individual animal levels.
Nevertheless, in the present study, a significant level of protec-
tion by BCG vaccination could be demonstrated based both on
reduction in the number of tissues with visible pathology and on the
reduction in granulomata severity. Thus, the significant reduction in
pathology following BCG vaccination could lead to a reduced
onward transmission rate from vaccinated cattle to other susceptible
cattle. This indirect vaccination effect would therefore very likely
contribute to a reduction in the prevalence of bTB from vaccinated
herds, as had been shown in an earlier trial in the UK (Doyle & Stu-
art, 1958). For example, BCG vaccination could reduce the incidence
of bTB in vaccinated herds to a level where more conventional test-
and-slaughter approaches could be affordable. The reduction in the
development of granulomas further confirms the finding of BCG
imparting protection by reducing pathology. From the disease trans-
mission point of view, this has great epidemiological implication, as
lesions that are confined with bacilli contained in granulomas at cer-
tain anatomical sites may also prevent disease transmission to other
animals (Johnson, Spencer, Hewinson, Vordermeier, & Wangoo,
2006).
5 | CONCLUSION
In conclusion, although the reduction in the proportion of suscepti-
ble animals through BCG vaccination (full protection, direct effect of
vaccination) was lower than that recorded in the previous study, the
significant reduction in the severity and distribution of visible and
microscopical pathology in vaccinated calves is likely to reduce
onward transmission to other animals (a so-called indirect vaccine
effect). This would have a beneficial impact on disease control in
vaccinated farms.
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